STAT+: As FDA raises bar in rare diseases, pivotal moment...

What’s Happening

Okay so A prominent biotech investor weighs in on the pros and the cons of the FDA’s new regime.

Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: JPM Week 2026 is over. (it feels like chaos)

Here’s why By Adam Feuerstein Adams Take Adams Take STAT Plus: Why the JP Morgan conference is important — but not make-or-break By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: Ocular Therapeutix faces looming test of a more durable eye treatment By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: Biotech, growing up, is turning profitable By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: Waves gym bro obesity drug is story over substance By Adam Feuerstein STAT Plus: Regeneron’s chief scientist on Trump’s drug pricing policy, gene therapy, and the problem with AI By Matthew Herper STAT Plus: Limit on multiyear funding of NIH grants is a sticking point in Senate budget talks By Anil Oza and John Wilkerson STAT Plus: At JPM 2026, Mehmet Oz and top Trump health officials explain their thinking to hospital leaders By Tara Bannow STAT Plus: Secretive Project Prometheus takes VC Bob Nelsen beyond just health care By Allison DeAngelis STAT Plus: JPM Week 2026 is over.

Why This Matters

Health experts are weighing in on what this means for people.

This is the kind of health news that affects everyday decisions.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

What do you think about all this?